Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
8(100.0%)
8Total
Phase 1(8)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT03487055Phase 1Unknown

Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

Role: lead

NCT03242512Phase 1Unknown

Assessment of Anti-RANKL Antibody in Post-menopausal Women

Role: lead

NCT03021785Phase 1Unknown

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

Role: lead

NCT02613559Phase 1Unknown

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

Role: lead

NCT03239756Phase 1Unknown

Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

Role: lead

NCT02643901Phase 1Completed

Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects

Role: lead

NCT02725606Phase 1Unknown

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Role: lead

NCT02156388Phase 1Completed

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

Role: lead

All 8 trials loaded